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Abstract:
Objectives:
Cognitive  impairment  may  affect  patients  with  Bipolar  Disorder  (BD)  beyond  the  acute  episodes,  qualifying  as  a  potential
endophenotype.  However,  which  cognitive  domains  are  specifically  affected  in  euthymic  patients  with  BD  and  the  potential
influence of confounding factors (e.g., age and concomitant pharmacological treatment) are still a matter of debate. The present study
was, therefore, conducted to assess cognitive performance across specific domains in euthymic bipolar patients, not older than 50
years (to avoid potential age-related bias) versus healthy controls (HCs).
Methods:
A cognitive task battery, including the Wisconsin Card Test, Span Attention Test, Tower of London, Trail Making Test, Verbal
Fluency  Test,  Matrices  Scores  and  N-Back,  was  administered  to  62  subjects  (30  bipolar  patients  and  32  matched  HCs)  and
differences between the groups analyzed.
Results:
Bipolar  patients  performed  significantly  worse  than  HCs  in  the  Span  Forward  task,  in  the  expression  of  Verbal  Fluency  Test
(Category) and in the N-Back task (all p<.05), with marginal differences between BD I and BD II patients.
Conclusion:
The present study pointed out significant differences in terms of cognitive performance between euthymic bipolar patients and HCs,
supporting the notion that specific cognitive functions may remain impaired even after the resolution of the acute episodes in subjects
suffering  from BD.  Future  studies  on  larger  samples  are  warranted  to  confirm the  present  results  and  further  explore  potential
differences in cognitive impairment across specific bipolar subtypes.
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BACKGROUND
Bipolar Disorder (BD) is a highly disabling condition with a complex gene-environment etiology [1]. Among the
core symptoms of BD, cognitive impairment seems to be a consistent feature during acute episodes [2, 3]. In particular,
cognitive  symptoms  have  been  extensively  investigated  during  depressive  episodes,  either  in  unipolar  and  bipolar
patients [4]. For instance, attentional deficit, impaired short- and long-term memory, decision making and judgement
have been reportedly observed in depressed patients and are among the criteria of Major Depressive Episode for DSM-5
[5]  and  ICD-10  [6].  Some  studies  point  out  that  cognitive  deficits  represent  an  early  feature  of  Major  Depressive
Disorder, with the involvement of executive functioning, attention, learning and memory, not only in the acute phase
but throughout the entire course of the disease [7]. Data from the literature show that cognitive deficits can improve
with pharmacological treatment [8, 9], but there is still uncertainty about which cognitive domains can be improved by
treatment [10].
On the other hand, executive functions, memory, attention and psychomotor speed were found to be significantly
altered in manic phases as well [11, 12]. In addition, cognitive impairment and general functioning were found to be
deeply interconnected with a profound impact on clinical outcome [11, 12].
The hypothesis that bipolar patients – or at least a part of them - may present cognitive impairment beyond acute
episodes has been supported by several reports and, more recently, meta-analytic studies [13 - 17]. In particular, the
presence  of  cognitive  impairment  during  euthymic  periods  was  found  to  negatively  influence  patients’  functional
outcome and global  performance [18],  like other  well-established clinical  features,  such as  the number of  previous
episodes [19] and the overall response to treatment [20].
Cognitive impairment,  therefore,  could be a specific trait  of BD and some studies have associated altered brain
activity, measured through imaging procedures, with cognitive deficits, suggesting that such domain may represent a
heritable, susceptibility-related phenotype [21]. According to a recent meta-analysis, moreover, a different expression of
cognitive dysfunction was reported in first-episode patients with BD [22] and in unaffected siblings of young bipolar
patients, providing more direct support for its potential heritability [23]. Arts and colleagues [24], in a previous meta-
analysis, indicated executive function and verbal memory as candidate bipolar endophenotypes, given the presence of
important deficits in these domains in bipolar patients as well as the existence of small cognitive impairment in first-
degree relatives. Follow-up studies on cognitive assessment of bipolar patients provide an additional confirmation in
this respect. In fact, Arts and co-workers [25] evaluated the cognitive profile of a group of patients over a 2-year follow-
up period and found that cognitive function varied significantly over time, with the exception of sustained attention that
may represent an intermediary phenotype.
Even  though  cognitive  functioning  has  been  indicated  as  a  promising  endophenotype  and  a  marker  of  global
functioning/prognosis  in  psychiatric  disorders,  studies  of  cognitive  performances  in  the  field  of  BD showed mixed
results. For instance, cognitive impairment was documented in specific areas, such as executive functions [26], memory
[27, 28] and attention span/processing speed in patients with BD [29, 30]. However, it is unclear whether cognitive
impairment is a general trait of BD (present, for instance, in BD I and BD II subjects), with investigation on potential
differences between BD I vs II types substantially lacking [31, 32]. In addition, a large variety of cognitive tasks have
been employed to assess cognitive impairment during euthymia, complicating the interpretation of results from different
studies  conducted  with  bipolar  patients  [33].  In  fact,  although  cognitive  impairment  is  recognized  as  an  important
clinical  feature  of  BD,  there  is  no  standard  cognitive  battery  that  has  been  developed  ad  hoc.  For  instance,  most
neuropsychological batteries used to test patients with Schizophrenia were found to be as accurate for testing patients
with BD as well [34].
Recently, it was shown that cognitive test measuring set shifting, inhibition/latency, verbal fluency and the ability of
detecting  differences  and  searching  (e.g.,  Trial  Making  Test,  Stroop  Color  Word  test)  had  the  strongest  ability  to
discriminate even subtle differences in the cognitive functioning of bipolar patients [33].
In  light  of  the  above  discussion,  the  main  aim  of  the  present  study  was  to  explore  cognitive  performances  in
euthymic bipolar patients, using a specific cognitive battery, recognised in literature as reliable for assessing cognitive
performance  in  psychiatric  patients  suffering  from  mood  disorders  [35].  In  addition,  the  study  was  conducted  on
patients under the age of 50 years, in order to reduce potential age-related influence over cognitive functioning. Finally,
we  aimed  to  assess  possible  differences  between  patients  suffering  from BD type  I  vs  type  II,  as  this  topic  is  less
considered in literature.
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MATERIALS AND METHODS
Sample
From an original sample of 65 bipolar patients, thirty patients with BD (15 patients with BD I and 15 with BD II)
and 32 healthy controls (HCs) were recruited for the study. The main reasons for exclusion from the protocol were age
> 50 years (90%) and mental retardation (10%). All participants were white Caucasian, who provided written informed
consent,  after  receiving  a  complete  description  of  the  study,  in  accordance  with  the  Declaration  of  Helsinki.  The
Structured Clinical Interviews for DSM-IV-TR [36 - 39] were used to confirm patients’ diagnosis and to exclude the
presence of any Axis I and II disorder for healthy subjects. All patients and controls were recruited by psychiatrists
working at the University Department of Mental Health at the Fondazione IRCCS Ca’ Granda, Ospedale Maggiore
Policlinico of Milan, Italy. Additional exclusion criteria were: inability to give informed consent, mental retardation, a
history of substance abuse within the past 6 months, the presence of any significant neurological and medical condition
revealed by clinical and MRI evaluation. Lifetime psychiatric comorbidities were accepted, while cross-sectional ones
were ruled out. When considering comorbidity, BD had to be the primary disorder, that is the one representing the main
motivation to seek help and responsible for the most significant distress.
All patients were on stable pharmacological treatment with mood stabilizers (lithium, anticonvulsants and atypical
antipsychotics) and, in some cases, antidepressants, for at least 8 weeks before entering the study. The class of drug
patients at  the time of the assessment was determined. The severity of depressive and manic residual symptoms, if
present, was evaluated by a certified psychiatrist through the Hamilton Depression Rating Scale (HAM-D) [40] and the
Young Mania Rating Scale (YMRS) [41]. All patients were required to be euthymic for at least 4 weeks prior to the
neuropsychiatric and neuropsychological evaluation, showing HAM-D ≤ 7 and YMRS ≤ 12 total scores.
Clinical Assessment and Neuropsychological Evaluation Paradigm
The following socio-demographic and clinical data of the sample were collected: age, gender, age of onset, years of
education, medical and psychiatric comorbidity, family history for psychiatric disorders, duration of untreated illness
(DUI), current treatment, lifetime number of manic/hypomanic/mixed and depressive episodes.
The  assessed  cognitive  functions  were:  visual  and  selective  attention,  executive  functioning,  mental  flexibility,
verbal fluency and working memory. In particular, all patients and controls underwent a cognitive examination held by
a professional neuropsychologist (M.C.) involving eight specific tasks: Stroop test -interference and errors- [42, 43],
Tower of London -score- [44, 45], Span Attention test (Backward and Forward), Raven Matrices (score/time), Trail
Making Task (partial score A, B and B-A) [46], Verbal Fluency Test (Category and Letter), Wisconsin Card Test (total
score/error/perseverance/global) [47, 48], N-Back task (0-Back, 2-Back, 3-Back and Reaction Time) [49].
Statistical Analysis
Descriptive analyses on socio-demographic and clinical data were performed using SPSS software, version 21.0. A
one-way ANOVA was performed, comparing main and partial scores of each test in bipolar patients vs HCs. A further
analysis was performed splitting patient sample into BD I and BD II groups (BD I vs BD II vs HCs). A post hoc test
with Bonferroni correction of the level of significance was performed, taking into account that multiple comparisons
have been performed with the same data, in order to assess possible differences among diagnostic subgroups.
RESULTS
Socio-Demographic and Clinical Findings
Main socio-demographic and clinical data of the study sample are summarised in (Table 1).
The sample consisted of 15 patients with BD I (53% males; mean age 34.3 ± 10.3 SD years), 15 patients with BD II
(54% males; mean age 37.3 ± 8 SD years) and 32 HCs (55.5% males; mean age 29.4 ± 10.6 SD years).
Table 1. Main socio-demographic and clinical characteristics of the total sample and diagnostic subgroups.
BD (n=30) BD I (n=15) BD II (n=15) HCs (n=32) P value
Gender (F:M) 11:19 6:9 5:1 14:18 0.1
Age (m + SD) 36.1 (+10.1) 34.3(+10.3) 38.0(+9.6) 31.2(+11.8) 0.4
Education in years (m + SD) 14.3 (+1.6) 14.5(+1.9) 14.0(+1.6) 14.9(+2.1) 0.3
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BD (n=30) BD I (n=15) BD II (n=15) HCs (n=32) P value
Age of onset (m + SD) 23.9(+6.8) 23.6(+5.8) 24.2(+7.9) - 0.8
Psychiatric comorbidity (%) 40.0 26.6 53.3 - 0.1
Medical comorbidity (%) 36.6 33.3 40.0 - 0.3
Positive family history for psychiatric disorders (%) 56.6 46.6 66.0 - 0.4
DUI (months) (m + SD) 26.2(+18.5) 13.7(+19.2)** 40.6(+50.7) - 0.0004
Number of depressive episodes (m) 6.3 4.0 7.0 - 0.2
Number of manic/mixed/hypomanic episodes (m) 6.6 6.3 7.0 - 0.1
Duration of last episode (days) 32.7 38.6 26.2 - 0.2
Monotherapy (%)
ADs
MSs
20.0
100.0
20.0
100.0
20.0
100.0
- 0.3
Values for categorical and continuous variables are expressed as n (%) and mean ± SD, respectively.
Standard deviations for continuous variables are shown in brackets.
Statistics: **F=8.503; p<.001
Legend: BD=Bipolar Disorder¸ BD I = Bipolar Disorder I patients, BD II= Bipolar Disorder II patients, HCs=Healthy Controls, DUI=Duration of
Untreated Illness; ADs=antidepressants; MSs=mood stabilizers (lithium, anticonvulsants and atypical antipsychotics)
Bipolar patients and HCs were homogeneous in terms of gender ratio, age and years of education.
Approximately half of the patient sample had a positive family history for psychiatric disorders, that was higher in
the BD II subgroup (66% vs 46% of BD I). BD II patients had twice the rate of psychiatric comorbidity compared to
BD I subjects (53% vs 26%), medical comorbidity being only slightly higher in the same group (40% vs 33%). While
the age of onset was comparable between BD I and II patients (23.6 vs 24.2 years), the duration of untreated illness
(DUI) was significantly lower in the BD I group (13.7 months vs 40.6 months; F=8.503, p<.001). Depressive episodes
were  more  common  in  BD  II  patients  (7  vs  4),  though  not  to  a  statistically  significant  level,  while  there  were  no
differences in terms of manic/hypomanic/mixed episodes between the two subgroups. Regardless of polarity, the mean
duration of the last episode was not statistically different between the two subgroups. Finally, concerning the treatment,
the 20% of the sample was treated with a monotherapy, regardless of diagnosis, polytherapy being definitively more
common within the bipolar patients’ sample.
Fig. (1a). Span Attention Test (Forward and Backward) in BD patients vs HCs.
(Table 1) contd.....
 
 
Legend: BD=Bipolar Disorder patients; HCs=Healthy Controls 
**=statistically significant (p<.001) 
 
** 
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Neuropsychological Findings
Results  of  the  one-way  ANOVA  comparing  bipolar  patients  and  HCs  in  terms  of  score  performances  are
summarized  in  (Table  2).
Table 2. Results of the neuropsychological battery administered to patients with BD vs HCs.
TEST BD (n=30) HCs (n=32) P value
Span Forward
(m+SD)**
5.8(+0.96) 6.5(+0.84) 0.0002
Span Backward
(m+SD)§
4.9(+1.1) 5.5(+1.2) 0.06
Verbal Fluency Test (categories)
(m+SD)**
44.6(+9.3) 51.1(+9.6) 0.0009
Verbal Fluency Test (letter)
(m+SD) §§
35.3(+13) 40.6(+10.4) 0.08
Trial Making Test (B-A)
(m+SD) §§
86.6(+32.2) 75.3(+15.8) 0.08
Matrices Score
(m+SD) §§
45.89(+4.9) 47.7(+2.8) 0.08
n-Back Total
(m+SD)**
0.81(+0.12) 9.89(+0.08) 0.0004
2-Back Test
(m+SD)*
10.13(+1.8) 11.28(+1.6) 0.01
3-Back Test
(m+SD)§
8.5(+2.4) 9.5(+1.5) 0.06
Values for categorical and continuous variables are expressed as n (%) and mean ± SD, respectively.
Standard deviations for continuous variables are shown in brackets.
Statistics:  One-way  ANOVA  *p<.05;  **p<.001;  §p=  0.06  (borderline  level  of  statistical  significance);  §§p=  0.08  (trend  level  of  statistical
significance)
Legend: BD=Bipolar Disorder patients; HCs=Healthy Controls
Fig. (1b). Verbal Fluency Task performance; Category and Letter task in BD patients vs HCs.
With respect to the attentional task, the Span Attention Test showed that bipolar patients obtained a lower score both
at the Forward (5.8 vs 6.5) and the Backward mode (4.9 vs 5.5), that turned out to be statistically significant for the
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Forward mode (p<.001), with a borderline statistical significance at the Backward mode (p=.06). Results of the Span
Attention Test are represented in (Fig. 1a).
The Verbal Fluency Test showed a significantly lower performance at the Category score in the BD group (44.6 vs
51.1, p<.001). The Letter score of BD patients was lower than HCs, showing a trend of statistical significance (p=.08).
Fig. (1b) shows the results of the Verbal Fluency Test.
With regard to the working memory task, the N-Back total score and 2-Back score were found to be significantly
lower in BD patients compared to HCs (p respectively <.001 and .05). The score at 3-Back performance was lower in
bipolar patients with a borderline statistical significance (p=.06) compared to HCs. Results of the Working Memory
task are represented in Fig. (1c).
Matrices total score and Trail Making Task (B-A test) showed a coherent trend, being lower in bipolar patients,
though not to a statistically significant level (p=.08).
After dividing the bipolar sample into subgroups, BD I and II patients showed significantly lower scores at Span
(Forward) Test (p<.001) compared to HCs. Considering post hoc Bonferroni analysis, BD-I patients had a significantly
lower score at Verbal Fluency Test (Category) compared to BD II and HCs (p<.001); conversely, at the 2-Back Task,
BD-II obtained lower scores compared to BD I and HCs (p<.001).
Fig. (1c). Working Memory: n-Back, 2-Back and 3-Back performance in BD patients vs HCs.
DISCUSSION
To date and to authors’ knowledge, this is the first study exploring cognitive functioning in patients with BD vs
HCs, with a specific comparison of BD I vs II patients. In addition, the sample of bipolar patients was selected focusing
on  subjects  under  the  age  of  50  (mean  age  of  36  years),  euthymic  for  at  least  8  weeks  and  during  a  stable
pharmacological  treatment.  The decision  to  exclude  senior  patients  was  taken in  order  to  minimize  a  possible  bias
occurring with the inclusion of patients potentially suffering from precocious and not yet diagnosed mild cognitive
impairment, caused by other neurological and vascular conditions.
Data on the characterization of the sample mostly reflected literature findings, with the only exception of age of
onset that was similar in the two groups, being usually lower in BD I individuals [50]. Otherwise, socio-demographic
and clinical features and treatment related variables were substantially consistent with what commonly reported from
studies in the field. The mean duration of untreated illness was not surprisingly lower in subjects showing more severe
and disturbing symptoms, as usually happens in BD I subjects due to manic episodes [51].
0
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  Legend:BD=Bipolar Disorder; HCs=Healty Controls 
*= statistically significant (p<.05) **=stastistically significant (p<.001)  
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Several  studies  reported  the  presence  of  cognitive  deficits  in  euthymic  bipolar  patients  [52].  More  in  detail,
impairment  in  executive functions  (in  particular  category fluency and mental  manipulation),  memory (in  particular
immediate and delayed verbal memory) and attention are the most consistently reported findings in the field [52]. Some
authors confirmed the presence of persistent neurocognitive deficits not only in the euthymic phase of BD but also in
bipolar patients with alcohol abuse, suggesting an adjunctive negative effect on memory and frontal executive functions
in bipolar individuals with this specific pattern of comorbidity [53].
In this perspective, our study supports previous findings and the notion of residual cognitive symptoms in euthymic
bipolar patients, showing a statistically significant impairment in the Forward Attention Task, in the Category Fluency
and in the Working Memory (n-Back and 2-Back test), compared to HCs. Nonetheless, it has to be noticed that, in the
present study, cognitive deficits were detected only in a part of the administered tests, with some statistical values of
borderline  significance,  suggesting  that  other  cognitive  functions  resulted  preserved.  Concerning  the  possible
confounding effect represented by comorbid alcohol abuse, we could exclude any interference caused by concomitant
abuse, as this was an exclusion criterion, but we did not assess lifetime comorbidity with alcohol abuse.
More in detail, attention represents the ability to focus on a specific task. When this function is impaired (as we
found in bipolar patients who had impairment in Forward Attention Task) patient are easily distracted. Attention is a
basic requirement for being able to perform other cognitive tests and, when this function is impaired, the results of other
tests  may  be  hardly  interpreted.  Verbal  fluency  requires  both  language  and  executive  skills;  common  assessment
techniques usually include asking patients to list as many things in a category (Category) or as many words beginning
with a specific letter (Letter) as they can, in a 1 minute period. The consequence of an impairment at these tests might
be represented by an altered structure of the language, which may be poor and, sometimes, difficult to understand. An
impaired working memory, as underlined by the worse results at N-Back test, indicates bipolar patients less able to plan
strategies and organize solutions to everyday life problems.
Taken  as  a  whole,  these  findings  might  be  useful  to  guide  research  on  specific  cognitive  domains  potentially
impaired in BD, memory and attention, in particular, given that our results were obtained from a group of young adults.
In addition, reported results may be particularly useful in order to assess the epoch of onset of cognitive symptoms in
bipolar patients. In fact, it has been reported that cognitive dysfunction has a significant impact on clinical outcome [11,
12,]. Hence, early identification and treatment of these symptoms are important in order to improve patients’ overall
prognosis and quality of life.
Cognitive alterations in some patients with BD are evident not only during the acute phase of the disease: some
studies, in fact,  found cognitive impairment even before the onset [54, 55]. Furthermore, other studies revealed the
presence of specific cognitive deficits also in patient’s relatives [24, 25, 56, 57], stressing the heritability of BD. The
present  study,  however,  did  not  include  a  sample  of  relatives  of  bipolar  patients,  being  this  issue,  for  future
investigation,  of  particular  relevance.
Another aim of the present study was to identify possible differences between the two subgroups of bipolar patients
(BD  I  and  BD  II),  being  the  argument  largely  neglected  by  the  available  literature.  In  this  regard,  only  minor
statistically  significant  differences  were  found  in  some  tasks  of  cognitive  assessment  when  comparing  bipolar
subgroups and HCs. In particular, BD I patients were found to perform worse on cognitive domains related to Verbal
Fluency (i.e., Verbal Fluency test, Category), while BD II subjects showed a worse performance in relation to Working
Memory (i.e., 2-Back Task).
These findings may suggest that cognitive dysfunctions may be present at the same level in both subtypes of BD,
supporting the notion that BD II subjects do not simply suffer from a milder form of BD, as recently pointed out in
European  and  American  studies  [58,  59].  Nonetheless,  the  hypothesis  that  euthymic  BD  I  and  II  subjects  may
additionally  show  specific  differences  in  terms  of  cognitive  impairment  remains  to  be  further  tested  within  larger
sample studies.
The  following  limitations  should  be  kept  into  consideration  in  the  interpretation  of  reported  results.  The  main
limitation of the study is represented by the limited sample, particularly in the comparison of the diagnostic subsamples.
This aspect reflected the screening process that brought to select only 30 subjects from 65 initial patients. Some of the
reported  results  showing  a  borderline  significance,  in  fact,  may  have  shown  more  robust  differences  with  larger
samples. For future research, extending the assessment with follow-up observation of cognitive evaluations of patients,
especially  in  the  euthymic  phases,  would  be  of  great  clinical  interest,  in  order  to  assess  whether  the  duration  of
intercritical periods could influence the cognitive profile of bipolar patients. Literature, in fact, suggests the persistence
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of cognitive impairment in the euthymic phases of BD for some patients. However, it is not possible to exclude that a
longer period of euthymia may lead to an improvement of the cognitive profile, with specific investigation in the field
highly necessary.
Another bias may be represented by the lack of IQ assessment in patients and HCs, with the number of years of
education used as an indirect evidence of the homogeneous intellective level of the sample. Furthermore, a potential
influence  of  concomitant  pharmacological  treatment  over  cognitive  functioning  between  bipolar  patients  and  HCs
cannot  be  ruled  out.  In  fact,  all  patients  were  taking  psychotropic  medications,  which  could  affect  cognitive
performance in the tests.  Furthermore, with regard to the pharmacological treatment,  we only recorded the class of
psychotropic compounds, without collecting nor analyzing the potential effect of any specific molecule, which might, in
turn, interfere with patient’s cognitive functioning. Finally, the sample was selected among patients attending a tertiary
Clinic, specialised in the diagnosis and treatment of BD in Italy, and such sample may not be necessarily representative
of the entire population of bipolar patients worldwide.
CONCLUSION
In conclusion, the present study pointed out the presence of specific cognitive deficits in adult euthymic patients
with BD compared with HCs, with marginal differences between bipolar I and II subjects. Further studies with larger
samples are needed to confirm present results and explore the epoch of onset, the associated clinical features and the
outcome influence of reported cognitive deficits in bipolar patients.
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